Prostate speci®c antigen (PSA, hK3) in serum is predominantly complexed to a-1-antichymotrypsin (ACT), but a minor fraction remains in a free form despite the very large excess of serine protease inhibitors and a-2-macroglobulin. The fraction of free to total PSA is signi®cantly lower in prostate cancer (CaP) compared to benign prostatic hyperplasia (BPH) which provides improved discrimination of these conditions. The molecular nature of free PSA in the circulation and the reason for its varying concentration in malignant and benign conditions is currently not known. The objective of the present investigation was to study the secretion of PSA and human glandular kallikrein 2 (hK2) by the LNCaP prostate cancer cell line, and to purify and characterize both proteins.
Introduction
Prostate speci®c antigen is a chymotrypsin-like serine protease that belongs to the human glandular kallikrein family. 1 PSA is predominantly produced by the human prostate and is secreted into the seminal¯uid, where it is found at concentrations of 0.2 ± 5 mg/ml. 2, 3 Normally only 10
76 of these levels of PSA are found in the bloodstream, but the concentration increases in various diseases of the prostate Ð particularly in prostate cancer. Serum PSA is the most commonly used tumor marker for the detection and monitoring of prostate cancer (CaP). 4 The diagnostic speci®city of PSA measurements is limited by the fact that PSA concentrations are frequently elevated also in subjects with benign prostatic hyperplasia (BPH).
Mature, active PSA forms stable complexes with a 1 -antichymotrypsin (ACT), a 2 -macroglobulin (AMG), a 1 -protease inhibitor and protein C inhibitor. 5 ± 7 PSA in serum is predominantly found complexed to ACT. 7 ± 8 Despite the 10 4 ± 10 5 molar excess of ACT, part of PSA remains in free form. The measurement of the proportion of PSA bound in complex in serum (complex/total or free/total) improves the discrimination between cancer and non-cancer patients. 7, 9 Since the complex formation between PSA and ACT or AMG involves a cleavage of the protease inhibitor, the protease must generally be enzymatically active to form the complex. 5, 10, 11 Since in the bloodstream there is a 10 5 -fold excess of protease inhibitors compared to PSA, any enzymatically active PSA is likely to be found in a complexed form. It is therefore reasonable to assume, that most of the free PSA in the circulation lacks enzymatic activity. PSA is synthesized as a 244 amino acid zymogen (proPSA), and is activated by proteolytic release of 7 aa at a monobasic site forming a 237 aa active enzyme ( Figure 1 ). The cleavage is done by an enzyme with trypsin-like substrate speci®city. Human glandular kallikrein (hK2) has been shown to be able to activate proPSA in vitro 12 ± 14 and is therefore a likely candidate for physiological activation of PSA in vivo since it is, likewise to PSA produced abundantly in the prostate epithelium. Further internal cleavage of the mature PSA renders the protein enzymatically inactive. 15 Zymogen forms of PSA or internally cleaved forms of PSA are two obvious possibilities for the presence of free PSA in the circulation.
The occurrence of 4 ± 6 PSA isoforms has been demonstrated by isoelectric focusing. Wang et al 16 found six isoforms of PSA with pI points 6.82 ± 7.53 in a crude extract of BPH tissue. Huber et al 17 reported similar results for samples from serum of BPH patients. Additionally they found isoforms with pI points ranging from 7.7 ± 8.3 in spent LNCaP medium and in serum of patients with advanced prostate cancer. They suggested that these isoforms could have different pI points due to a smaller number of sialic acid residues than isoforms found in serum and BPH tissue. The cause of the observed differences in pI values has not however been unequivocally shown.
LNCaP is a human metastatic prostate adenocarcinoma cell line. The strain was isolated in 1977 by Horoszewicz et al 18 from a needle aspiration biopsy of the left supraclavicular lymph node of a 50 y old Caucasian male with con®rmed diagnosis of metastatic prostate carcinoma. The cell line has a mutated androgen receptor and it is sensitive to several androgens, anti-androgens, estrogens and progestins. 19 ± 21 The objective of this study was to optimize production levels and purify PSA and hK2 from the adenocarcinoma cell line LNCaP, to clarify antigenic, structural and enzymatic characteristics of the protein forms secreted into the growth medium and study the ability of recombinant hK2 to activate proPSA secreted by LNCaP cells.
Materials and methods

Materials and reagents
The production and characterization of mAbs 2E9, 3C1, 5A10, 5F11, 9B10, 9E8 and 10D7 has been described earlier. 8 22 The¯uorogenic structure Lys-Gly-IleSer-Ser-Glu-Tyr-AMC for PSA was kindly provided by Prof J T Isaacs, John Hopkins Oncology Center, Baltimore, MD. The¯uorogenic substrate H-Pro-Phe-Arg-AMC for hK2 was obtained from Bachem (Budendorf, Switzerland).
Production and puri®cation of LNCaP PSA
The human metastatic prostate adenocarcinoma cell line LNCaP (ATCC, Rockville, MD) was grown in Dulbeccos Modi®ed Eagle's Medium (DMEM) (Life Technologies, Gibco BRL, Grand Island, NY) with and without 10% heat inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT) and 5 nM synthetic hormone methyltrienolone (R1881) (New England Nuclear, Boston, MA). Charcoal stripped bovine calf serum was obtained from Sigma (St. Louis, MO). When cells were grown in medium without serum, 0.2% bovine serum albumin (BSA) (Sigma) was added instead of serum.
The cells were grown in 75 cm 2 culture¯asks (Corning Costar Corporation, Acton, MA) until near con¯uency. The cells were dispersed with a trypsin-EDTA solution (ICN Biomedicals, Costa Mesa, CA) and new¯asks were inoculated with cell suspensions. The cells were maintained at 37 C in a humidi®ed atmosphere of 5% CO 2 . Cell culture medium was changed at 4 ± 7 day intervals. PSA was puri®ed from growth media with two Af®-Gel 1 10 af®nity columns (BioRad laboratories, Richmond, CA) containing anti-PSA antibodies. Centrifuged medium supernatant was ®rst passed through a 3 ml column containing 17 mg of immobilized mAb 5A10 which is speci®c for the free form of PSA and does not crossreact with hK2. Then the medium passed through a 2 ml column containing 12 mg of immobilized mAb 2E9 which reacts with both free and PSA found in complex with serpins, but likewise to mAb 5A10 does not crossreact with hK2. Finally, the PSA-depleted media was then passed through a column that contained 12 mg of mAb H50, which recognizes PSA and hK2 with similar af®nity for both proteins. 23 The puri®cations were performed in essence as described by Lo È vgren et al.
12
Immunometric measurements
The concentrations of free and total PSA were measured with the commercial Prostatus 1 PSA free/total kit (Wallac, Turku, Finland). The antibodies for total PSA used in the assay also recognize hK2, so any hK2 in the sample will add to the total PSA measured. This was not a problem however, since we also used free PSA and hK2 speci®c immunoassays. Complexed PSA could therefore be calculated as total PSA minus free PSA and hK2. The PSA-ACT complex was measured as previously reported 24 and speci®c measurement of hK2 was done using an improved modi®cation of the immunoassay described by Piironen et al. 25 Epitope mapping of LNCaP PSA was done using 18 anti-PSA monoclonal antibodies in two-site combinations. The measurements were done in essence as previously described. 24 
Analytical protein techniques
Amino-terminal sequence analyses were performed with an Applied Biosystems model 477A pulsed liquid sequencer connected to an online Applied Biosystems model 120A phenylthiohydantoin amino acid analyzer (Perkin Elmer, Norwalk, CT).
Gel ®ltration was done using the Pharmacia Smart system. 100 ml of LNCaP culture medium (1.2 mg/ml) was run through a Superose 12 column (Pharmacia) with phosphate buffered saline (pH 7.4). Flow rate was 0.2 ml/min and 250 ml fractions were collected. Af®nity puri®ed free PSA was further treated by reverse phase chromatography to obtain suitable samples for mass spectrometry. 70 mg of PSA was applied to a Pharmacia mRPC C2/C18 PC 3.2/3 column. The protein was eluted from the column with a 35 ± 40% increasing gradient of acetonitrile (0.1% TFA). The¯ow rate was 0.02 ml/min and the proportion of acetonitrile was increased by 1.25% ml. Samples for mass spectrometry were mixed with 0.5 ml of 10 mg/ml sinapinic acid in 60% acetonitrile/0.1% TFA/H 2 O and analyzed by matrix assisted laser desorption mass spectrometer (MALDI-MS, LASER-MAT, Finnigan MAT Ltd., UK).
SDS-PAGE and Isoelectric focusing were done using PhastSystem equipment and PhastGel 1 Homogeneous 20, IEF 3-9 and IEF 5-8 gels (Pharmacia).
Characterization of enzymatic activity
Kinetic measurements of enzymatic activity were done as described by Lo È vgren et al, 12 using the substrates KGISSQY-AMC and PFR-AMC for PSA and hK2 respectively. Activated recombinant proPSA 12, 23 was used as a positive control.
Activation of LNCaP PSA
Activation of proPSA with hK2 was achieved by incubating 1 mg of recombinant proPSA or 5A10-puri®ed LNCaP PSA (mixture of mature PSA and proPSA) with 0.01 ± 0.1 mg of recombinant hK2; 12 this was done in 10 ml of 50 mM Tris (pH 7.5) buffer containing 0.1 M NaCl for 4 h at 37 C.
Results
Immunological characterization
Epitope mapping showed that the extensive panel of 18 currently available mAbs recognized PSA secreted into the growth medium by the LNCaP cells by apparently identical af®nity compared to PSA isolated from seminal plasma.
Effect of culture conditions on protein production
After three days, the production of PSA reached a level of about 150 mg/l in both the growth medium without any fetal bovine serum (FBS) and in the growth medium containing charcoal stripped FBS. LNCaP cells secreted about 500 mg/l of PSA in the FBS containing growth medium. Addition of 5 nM R1881 nearly tripled the concentration of total PSA when there was no FBS or when there was charcoal stripped FBS in the medium. About 600 mg/l PSA was secreted when the growth medium contained both FBS and synthetic hormone. The changes in levels of hK2 secreted into the growth medium paralleled the changes in levels of PSA. Therefore the level of hK2 corresponded to 3.5 ± 5.0% of that of PSA in all growth media (Figure 2 ).
Characterization of complexed forms of PSA secreted into growth medium PSA complexes were present only when the growth medium contained FBS, so PSA secreted into growth medium without FBS was all in free form. In the growth medium containing FBS 91% of the PSA secreted by LNCaP cells occurred in free form (f-PSA). The remaining 9% was a PSA complex. The complex however, was not PSA-ACT, since it was not detected by the PSA-ACT speci®c immunoassay. LNCaP PSA grown in medium containing FBS eluted from the gel ®ltration column in two peaks. The ®rst minor peak eluted at a volume corresponding to a molecular mass of 87 kDa and the second major peak constituting about 90% of the immunoreactivity eluted at a volume corresponding to a mass of 30 kDa. PSA secreted into the growth medium without FBS eluted in one peak at the volume corresponding to 30 kDa.
Protein puri®cation
The LNCaP growth medium contained from 1.0 ± 2.7 mg of total PSA. The recovery of the proteins ranged between 44 ± 56%. The purity of the free PSA samples was evaluated by SDS-PAGE. This method showed that more than 90% of 5A10-puri®ed free PSA migrated as a single band independent of whether the sample was non-reduced or reduced prior to analysis (Figure 3 ).
Amino-terminal sequencing and mass spectrometry
According to the amino-terminal sequencing a major part of the LNCaP PSA recovered by af®nity chromatography using mAb 5A10 was in zymogen form. About one third was in a zymogen form starting from aa 7 5 (L-I-L-S-R-), about one third was in zymogen form starting at aa 7 7 (A-P-L-I-L-) and about one third had the mature PSA sequence I-V-G-G-W-. Less than 5% represented a mature form of PSA truncated at the amino terminal and therefore starting as aa 5 (W-E-C-E-K-). Any more extensively cleaved forms of PSA were not found. No reproducible differences were seen between PSA obtained from cells grown in media with or without FBS.
Also the complex form of PSA was recovered from growth medium containing FBS using af®nity puri®ca-tion with the 2E9 mAb column, which followed the removal of free PSA by the 5A10 mAb column. Aminoterminal sequencing revealed only the presence of the mature form of PSA in this sample. It also showed the presence of an equimolar amount of internally cleaved bovine a 1 -antiproteinase Ð sequences starting from aa 25 and aa 381 were found. 26 Noteworthy was also the ®nding that neither amino-terminal sequencing, nor SDS-PAGE were able to indicate the presence of any internally cleaved forms of PSA. Reverse phase chromatography was used to further purify the samples recovered from the 5A10 mAb column. Two protein peaks were recovered. The ®rst one eluted at about 39.0% acetonitrile, and the second peak at 39.5% acetonitrile. PSA contained in the ®rst peak had a mass of 28 110 Da and PSA from the second peak had a mass of 28 880 Da. Amino-terminal sequencing veri®ed, that the ®rst fraction contained mainly the mature form of PSA and most of the second fraction was proPSA starting from aa 7 7. Both samples contained a minor amount (about 20%) of PSA starting at aa 7 5.
Isoelectric focusing
Theoretically the arginine in the propeptide should cause a detectable shift in the pI compared to that of the mature form of PSA. 5A10-puri®ed LNCaP PSA showed several isoforms of PSA with pI points of 6.3 ± 7.5. Additionally two clear bands could be seen with pI points of 8.2 and 8.4. LNCaP PSA was activated by incubation with enzymatically active recombinant hK2 to study which of the detected isoforms contained proPSA. After activation the two bands with pI points of 8.2 and 8.4 clearly disappeared, showing that the isoforms with most basic pI (Figure 4) . The shift of pI resulting from activation was at least 0.7 pI units. PSA puri®ed from seminal plasma, which is all in mature form, formed a similar pattern of bands with pI points 6.4 ± 7.4 as activated LNCaP PSA.
Characterization of enzymatic activity
The PSA activity measurements with a¯uorogenic substrate showed that the 5A10-af®nity puri®ed LNCaP PSA grown in medium with 10% FBS had very little activity. It cleaved 3.21 pmol of the KGISSQY-AMC substrate/min. Incubation of proPSA with hK2 causes the PSA zymogen to turn into active, mature PSA. 12 After activation with recombinant hK2, the same amount of sample processed 16 pmol/min. LNCaP PSA puri®ed from medium that did not contain FBS had an activity of 14 pmol/min. After activation with hK2, this sample had an activity of 39 pmol/min. The activated recombinant PSA control samples had activities of 44 pmol and 47 pmol substrate/min. (Figures 5 and 6 ).
The hK2 activity measurements with the¯uorogenic substrate H-PFR-AMC showed, that the LNCaP hK2 isolated from growth medium with 10% FBS had no detectable activity. LNCaP hK2 puri®ed from medium that did not contain FBS had an activity of 63 pmol substrate/min. Recombinant hK2 expressed by baculovirus in insect cells had an activity of 55 pmol/min.
The samples of puri®ed LNCaP PSA were also tested for the presence of contaminating enzymatic activity of hK2 using the H-PFR-AMC substrate. However, no hK2 activity could be demonstrated in these samples.
Discussion
The objective of this present study was to characterize the forms of glandular kallikreins secreted by the prostate cancer cell line LNCaP, as this may provide valuable information relevant for our understanding of the corresponding forms found in prostate tissue and in serum of prostate cancer patients. The immunological characterization of PSA secreted by LNCaP cells suggested identity of the antigenic epitopes exposed by the LNCaP PSA and that isolated from seminal plasma. This study was also Figure 4 Isoelectric focusing pH 3 ± 9 from isolated LNCaP PSA. 0.8 mg of total protein was loaded. Lanes 1 and 5, pI markers; lentil lectin-basic, pI 8.65; lentil lectin-middle, pI 8.45; lentil lectin-acidic, pI 8.15; horse myoglobin-basic, pI 7.35; horse myoglobin-acidic, pI 6.85; human carbonic anhydrase, pI 6.55; bovine carbonic anhydrase, pI 5.85; b-lactoglobulin, pI 5.2; soybean trypsin inhibitor, pI 4.55; amyloglucosidase, pI 3.50. Lane 2, 5A10 puri®ed LNCaP PSA before activation with hK2; Lane 3, 5A10 puri®ed LNCaP PSA after activation with hK2; Lane 4, single chain PSA isolated from seminal¯uid. LNCaP PSA characterization V Va Èisa Ènen et al performed to con®rm the justi®ed use of the previously developed immunoassays to measure the levels of free PSA, total PSA and hK2 produced by the LNCaP cells.
LNCaP cells clearly grew faster and produced more PSA in the presence of 10% FBS compared to medium with no serum or medium containing charcoal stripped serum. In the latter two media, the levels of both hK2 and PSA produced nearly tripled when synthetic hormone R1881 was added. The effect of the hormone was relatively small in growth medium containing 10% FBS. These results are in accord with the previous results obtained by Wu et al. 27 The levels of hK2 secreted by the LNCaP cells corresponded to 3.4 ± 5.0% of those of PSA in all growth media tested. The variations measured are very slight and conceivably caused by differences in the initial cell number or stability of hK2 in media of different composition.
LNCaP cells, under all different conditions tested, secreted approximately equal amounts of two zymogen forms and the single-chain mature form of PSA. A small fraction of the mature form was truncated amino-terminally and therefore started from aa 5. We found no evidence for the presence of any internally cleaved PSA. A minor part (about 9%) of PSA secreted by LNCaP cells grown in medium containing FBS was found in complex with the bovine a 1 -antiproteinase, but we were not able to detect any PSA-ACT complexes released from the LNCaP cells. The lack of PSA-ACT in the growth medium is consistent with previously reported data 27 suggesting the amounts of ACT produced by the LNCaP cell line are so small, that they may not contribute to any signi®cant complexation with PSA.
Mature PSA and 7 7 proPSA were separated by reverse phase chromatography. Mature PSA had a mass of 28 110 Da by mass spectroscopy, which is very close to though slightly lower than, the result of 28 430 Da reported by Be Âlanger et al. 28 The 7 7 proPSA had a mass of 28 880 Da, which is close to the expected mass, as the calculated peptide mass of the seven amino acids in the zymogen form is 750 Da.
Wang et al 16 found six isoenzymes of PSA with pI points 6.82 ± 7.53 in the tissue from patients with BPH. We observed several isoforms of LNCaP PSA on the isoelectric focusing gels, of which most had pI points similar to the Pi : s of isoforms reported by Wang et al. 16 Additionally we found two bands with pI points of 8.2 and 8.4 in medium from LNCaP cells. These isoforms were not present in PSA isolated from seminal plasma. The bands became more acidic and shifted to pI points of 7.5 or less when LNCaP PSA was activated with recombinant hK2. It therefore seems obvious that the PSA isoforms with pI points of 8.2 and 8.4 correspond to the 7 5 and 7 7 zymogen forms of PSA.
Huber et al 17 also reported on the presence of PSA isoforms with pI 8.3. They were not able to ®nd these isoforms in serum of patients with BPH, but detected them in LNCaP medium and in the serum of several patients with advanced prostate cancer. Since we have now shown that the high pI isoforms are caused by the zymogen form of PSA, the speci®c measurements of the fraction of proPSA of the total free PSA concentration in serum samples may potentially provide additional information enhancing the discrimination of prostate cancer from benign conditions. In a recent study Mikolajczyk et al 29 found a 7 4 form of proPSA in serum samples pooled from patients with prostate cancer after separation with hydrophobic interaction chromatography. In contrast, Noldus et al 30 did not ®nd any proPSA in serum of patients with prostate cancer and bone metastasis. However, their PSA preparation might have contained contaminating hK2, since the puri®cation procedure used would not have removed this enzyme. The hK2 is likely to activate any proPSA originally contained in the samples. According to our results, it is clear that PSA is produced and secreted in several molecular forms, and these can probably also be found in serum samples. This must be taken into account when designing international standards for PSA assays, and the ability of currently used antibodies to equally recognize these forms of PSA must be tested.
The puri®ed free PSA and hK2 manifested enzymatic activity when LNCaP cells were grown in medium without FBS. The PSA activity was consistent with the amount of mature PSA in the sample. Activating LNCaP PSA with recombinant hK2 further increased the PSA activity in the sample to an extent compatible with that expected based on the amount of proPSA in the sample.
By contrast, both free PSA and hK2 puri®ed from medium containing FBS were inactive, as they cleaved only trace amounts of their corresponding synthetic peptide substrates. Again, chymotrypsin-like enzymatic activity typical for PSA appeared when the puri®ed LNCaP PSA was incubated with recombinant, active hK2. The enzymatic activity generated by this activation procedure was in agreement with that expected based on the amount of proPSA in the sample. The mature form of PSA in the sample remained inactive.
In addition to the reported data, the two previously mentioned studies 29, 30 of free PSA isolate from serum also reported on the presence of mature, yet uncomplexed PSA. It therefore seems, that mature, one-chain, free PSA can be inactive, when it is in contact with serum. The reason for this inactivity is currently unknown. Since part of the PSA secreted in medium with FBS did form a complex with bovine antiproteinase, the inactivation seems to be slow Ð allowing for complex formation with protease inhibitors. Still, there is a yet unknown regulation method for serum PSA in addition to zymogen secretion, internal cleavage and inactivation by protease inhibitors. It might be possible that a small molecular inhibitor of PSA and hK2 is present in FBS. No indications of the presence of such an inhibitor were obtained from amino-terminal sequencing, SDS-PAGE or mass spectrometry. Investigation of this matter should prove of great value to the understanding of the regulation of serine proteases in the circulation.
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